Drug intelligence / Profile preview

PDLYT7

Development stage: Unknown
Lead developer: NIPRO

Overview

**PDLYT7** is an investigational Nipro medicinal product being evaluated for use during maintenance hemodialysis or hemodiafiltration in adults with chronic kidney disease. A randomized, open-label Phase 3 crossover study compares dialysis performed using PDLYT7 with an active control dialysis drug, with primary evaluation of removal rates for urea nitrogen, creatinine, and uric acid. Its chemical composition, formulation details, and molecular mechanism have not been publicly disclosed.

Targets

CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on PDLYT7.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PDLYT7.